FDA approves Biogen's process for Tysabri production

04/17/2009 | Boston Globe (tiered subscription model), The

Biogen Idec secured FDA approval for its high-titer procedure used to produce Tysabri, a drug for treating relapsing types of multiple sclerosis and moderate-to-severe active Crohn's disease. The company now expects a fourfold increase in production, said Bob Hamm, Biogen's chief operating officer.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX